PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Wednesday reported a loss of $182.7 million in its third quarter.
The Palo Alto, California-based company said it had a loss of 95 cents per share.
The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 88 cents per share.
The rare disease drug developer posted revenue of $120.7 million in the period, topping Street forecasts. Seven analysts surveyed by Zacks expected $105.5 million.
BridgeBio Pharma shares have more than doubled since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $66.80, more than doubling in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
